Wall Street analysts expect Catalent Inc (NYSE:CTLT) to report earnings of $0.64 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Catalent’s earnings, with the highest EPS estimate coming in at $0.66 and the lowest estimate coming in at $0.61. Catalent reported earnings of $0.67 per share in the same quarter last year, which indicates a negative year over year growth rate of 4.5%. The business is expected to report its next quarterly earnings results on Tuesday, August 27th.
On average, analysts expect that Catalent will report full year earnings of $1.86 per share for the current fiscal year, with EPS estimates ranging from $1.82 to $1.89. For the next fiscal year, analysts forecast that the company will report earnings of $1.98 per share, with EPS estimates ranging from $1.93 to $2.09. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Catalent.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.42 by $0.07. The company had revenue of $617.50 million during the quarter, compared to the consensus estimate of $644.88 million. Catalent had a net margin of 6.01% and a return on equity of 16.78%. Catalent’s revenue was down 1.7% compared to the same quarter last year. During the same period last year, the firm earned $0.41 earnings per share.
In related news, Director Gregory T. Lucier purchased 2,000 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was acquired at an average price of $45.08 per share, with a total value of $90,160.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter L. Buzy purchased 44,500 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was bought at an average cost of $45.13 per share, with a total value of $2,008,285.00. Following the acquisition, the insider now owns 44,500 shares of the company’s stock, valued at approximately $2,008,285. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 56,500 shares of company stock valued at $2,542,845. Corporate insiders own 1.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Premia Global Advisors LLC purchased a new position in shares of Catalent in the first quarter worth $26,000. Rockefeller Capital Management L.P. purchased a new position in shares of Catalent in the first quarter worth $31,000. Sageworth Trust Co purchased a new position in shares of Catalent during the first quarter worth $32,000. Fifth Third Bancorp raised its holdings in shares of Catalent by 85.2% during the first quarter. Fifth Third Bancorp now owns 1,000 shares of the company’s stock worth $41,000 after purchasing an additional 460 shares during the last quarter. Finally, Quantamental Technologies LLC purchased a new position in shares of Catalent during the fourth quarter worth $47,000. 96.85% of the stock is owned by institutional investors and hedge funds.
CTLT traded up $1.03 during trading on Friday, hitting $47.06. The stock had a trading volume of 12,731 shares, compared to its average volume of 677,725. The company has a market cap of $6.82 billion, a price-to-earnings ratio of 29.65, a price-to-earnings-growth ratio of 2.42 and a beta of 1.57. Catalent has a twelve month low of $29.23 and a twelve month high of $47.04. The company has a quick ratio of 1.71, a current ratio of 2.18 and a debt-to-equity ratio of 1.31.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: What is the formula for the cash asset ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.